Abstract
Importance Biomarkers for the early detection of Parkinson’s disease (PD) are needed; emerging evidence implicates immune dysregulation. Altered leukocyte differentials and C-reactive protein (CRP), common markers of immune function, occur in patients with PD. Whether these changes drive pathogenesis remains unclear.
Objectives We sought to identify whether peripheral immune dysregulation can be seen as a pre-diagnostic feature of PD, and whether it appears to play a causal role.
Design We examined the relationship between differential leukocyte count and other markers of acute inflammation at enrolment, and incident cases of PD, in UK Biobank, a longitudinal cohort study. We used Mendelian randomization to establish whether differences in leukocyte subsets have a causal influence on risk of PD.
Setting The UK Biobank; a population-based cohort with over 500,000 participants aged 40-69 recruited in the UK between 2006 and 2010.
Participants PD cases were defined as individuals with an ICD-10 coded diagnosis of PD. Cases were defined as ‘incident’ if their age at diagnosis was greater than their age at recruitment to UKB. ‘Controls’ were defined as all other individuals in the dataset after applying the above exclusions. After applying exclusion criteria for pre-existing health conditions that can influence blood counts, 507 incident PD cases and 328,280 controls were included in the analysis.
Exposure Blood cell markers (absolute and relative counts) and other markers of inflammation (CRP and albumin) were obtained from blood tests of participants taken at the initial assessment visit.
Results Lower lymphocyte count was associated with increased risk of incident PD. There was weaker evidence of association between lower eosinophil and monocyte counts, lower CRP, and higher neutrophil counts on risk of incident PD. The association between lymphopenia and incident PD remained robust to sensitivity analyses. Mendelian randomization did not reveal a clear causal effect of low lymphocyte count on PD risk, but a weak trend in that direction was seen.
Conclusions and relevance In this large, prospective setting, lower lymphocyte count was associated with higher risk of subsequent PD diagnosis. The absence of a clear causal effect indicates that lymphopenia might be a consequence of prodromal PD.
Question Is the leukcoyte differential count a feature of pre-diagnostic Parkinson’s disease?
Findings In the UK Biobank, a longitudinal cohort study with over 500,000 participants, lower lymphocyte count was associated with a 23% increased odds of incident PD, a significant difference.
Meaning Pre-diagnostic Parkinson’s disease is associated with lower lymphocyte counts; this could enhance positive predictivity in algorithms designed to identify groups at higher risk of future Parkinson’s disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Preventive Neurology Units is funded by the Barts Charity. Melanie Jensen received support from the Isaac Schapera Trust and Benjamin Jacobs is an NIHR Academic Clinical Fellow. The funding bodies had no role design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
n/a
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
UK Biobank data are available via application (https://www.ukbiobank.ac.uk/). Code is available at https://github.com/benjacobs123456/PD_FBC_UKB. PD GWAS summary statistics are from Nalls et al. 2019, available via application at 23andMe https://research.23andme.com/dataset-access/. Generated GWAS summary statistics are available via the UK Biobank returns catalogue and on request to authors.
